Contact Us: 1-888-667-3325 /

Subscriber Content Preview | Request a free trialSearch  


Cardiac medical device M&A may not skip a beat

Following the $3.4 billion acquisition of Thoratec by St. Jude Medical, other cardiac medtech companies could prove attractive. Continue reading

Clinton attacks activist funds with an eye on corporate donors, Iowa diners

Hiking taxes on shorter investor holding periods and having activists disclose their stakes earlier comes right out of the Marty Lipton playbook and would be a boon to corporations Continue reading

Medical device company ViewRay raises $26.7M, goes public in reverse merger

The newly public company says it expects $70 million in revenues from business already booked. Continue reading

CytoDyn raising capital for Phase 3 trial of HIV drug

The company's PRO 140 antibody suppressed the virus for 11 months in patients who participated in a recent study. Continue reading

Tonix Pharmaceuticals raising $17 million to see drug trials through

The company is going back to capital markets for the second time this year, after the FDA approved a name for Tonix's lead drug. Continue reading

Stericycle buys Shred-it International for $2.3B

Target's backers cancelled a planned public offering for the company and instead sold it outright. Continue reading

TMT, healthcare help carry deal activity to record levels

Six-month M&A in the U.S. hits unprecedented heights, resulting in more than $1 trillion worth of transactions mostly driven by strategic buyers' hunger for growth that they can't achieve organically. Continue reading

Veterinary practice group Capna retains RBC for a sale process

The process is in its early stages and could bring in as much as $375 million. Continue reading

Helios retains Bank of America and Credit Suisse for a sale

The benefits management company, which is backed by Kelso and Stone Point Capital, could be worth $1.5 billion to $1.9 billion. Continue reading

As time goes by, shareholders gain power but add little

An alternative to single or dual class structures, popular in France, seems to have no effect on valuation. Few U.S. companies adopt the scheme, which encourages long-term holdings. Continue reading

To win a proxy fight, win the heart of a qualified board nominee

As insurgencies proliferate, investors and targets are fishing in the same limited pool of candidates. Experienced executives are the ideal recruits -- and companies may have an advantage over activists. Continue reading

Obamacare ruling expected to intensify healthcare M&A

Hospitals, REITs and insurers are likely to benefit from the Supreme Court's decision in King v. Burwell. Continue reading

Meet the journalists

William Blair's Dan Shedivy sits down to talk M&A in the healthcare services sector

Middle Market healthcare deals stayed strong in 2014 but were relative ... Video

More Healthcare video

The Deal's Webcast Series

If you have not had the chance to enjoy our Webcast Series, now is the time. Join these free 60-minute discussions and get a handle on the latest strategies and tactics in private equity, cross-border and middle market dealmaking and more.

Industry Events

View information on all upcoming industry events which The Deal representatives are participating in.

The Deal Economy Event

Our senior journalists host the industry's leading forecasting event, where influential members of the deal community discuss the outlook for dealmaking.

The Deal on Twitter

Follow @TheDealNewsroom for the latest news across mergers and acquisitions, auctions, financings, restructurings and more!